logo
Yatra Online Inc (YTRA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Yatra Online Inc (YTRA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Yahoo31-05-2025

Annual Revenue: INR7.9 billion (approximately USD93.1 million), up 90% year-over-year.
Quarterly Revenue (Q4): INR2.2 billion (approximately USD25.7 million), up 114% year-over-year.
Revenue Less Service Cost (Q4): INR1.1 billion (approximately USD12.8 million), up 34% year-over-year.
Adjusted EBITDA (Annual): INR344 million (approximately USD4 million), up 28% year-over-year.
Adjusted EBITDA (Q4): INR90 million (approximately USD1.1 million), up 23% year-over-year.
Net Profit (Annual): INR24 million (approximately USD0.3 million), a 106.5% improvement year-over-year.
Cash and Cash Equivalents: INR1,906 million (approximately USD23 million) as of March 31, 2025.
Gross Debt: Reduced to INR546 million (approximately USD6.4 million) as of March 31, 2025.
Corporate Client Acquisition (Q4): 35 new clients, contributing INR1.4 billion in expected annual volumes.
Corporate Client Acquisition (Annual): 148 new clients, contributing INR7.5 billion in expected annual volumes.
Warning! GuruFocus has detected 5 Warning Signs with YTRA.
Release Date: May 30, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Yatra Online Inc (NASDAQ:YTRA) reported a 90% year-over-year increase in annual revenues for FY25, reaching INR7.9 billion (approximately USD93.1 million).
The company's adjusted EBITDA rose by 28% year-over-year, highlighting disciplined execution and profitability.
Yatra Online Inc (NASDAQ:YTRA) added 148 new corporate clients in FY25, contributing to INR7.5 billion in expected annual volumes, reinforcing its market position.
The MICE business showed significant growth, handling over 600 trips and serving more than 80,000 travelers in FY25, with expectations to become a top three player in the segment.
The integration of new distribution capabilities (NDC) enhances the booking experience for corporate travelers, offering more flight options and better pricing.
The geopolitical tensions between India and Pakistan temporarily disrupted travel demand, particularly affecting the northern part of India, which accounts for 25-30% of Yatra's business volumes.
The B2C Air business faced a decline in gross bookings, with a 6% drop in Q4, although stabilization was noted.
The company faces competitive headwinds in the B2C segment, impacting growth potential.
Legal and professional fees related to corporate restructuring have increased operating costs.
The process of converting shares into India shares involves complex procedures across multiple jurisdictions, with no specific timeline for completion.
Q: Dhruv, if the situation were to further deteriorate along the Pakistan border, how much of the business has historically been tied to that region? A: Dhruv Shringi, CEO: The northern part of India accounts for about 25% to 30% of our overall business volumes. If tensions escalate, over 30% of our business could be impacted, considering both the origination and endpoint of travel in this region.
Q: What can you tell us about the proposed corporate structure and its implications for share fungibility? A: Dhruv Shringi, CEO: We have a structure in place that works across multiple jurisdictions. The next steps involve ensuring all procedural aspects are implemented over the coming months. This structure is a significant achievement, and we expect more clarity in the next two to four months.
Q: Are there acquisition opportunities in the MICE sector that could accelerate growth? A: Dhruv Shringi, CEO: We continue to evaluate opportunities. We completed an acquisition about six to seven months ago and are integrating it. Once this is done, we will be free to explore further opportunities.
Q: How much capacity do you have for future revenue growth before needing significant investments in OpEx? Can you grow the business 50% without major cost increases? A: Dhruv Shringi, CEO: We believe we can grow 30% to 40% without significantly altering our cost structure. The current increase in operating costs is mainly due to legal and professional fees related to the structural changes, not operational expansion.
Q: What are the key drivers for your FY26 growth guidance? A: Dhruv Shringi, CEO: We anticipate 20% growth in revenue less service cost and 30% adjusted EBITDA growth, driven by expansion in corporate travel, scaling of MICE and hotels, and full cost synergies from Globe Travels.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)
Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)

Yahoo

time27 minutes ago

  • Yahoo

Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)

Insmed Incorporated (NASDAQ:INSM) is among the 13 Biotech Stocks with Huge Upside Potential. Kelly Shi of Jefferies has given Insmed Incorporated (NASDAQ:INSM) a buy recommendation, stating that she is confident in the TPIP treatment's impending Phase 2 data for pulmonary arterial hypertension. A biopharmaceutical research team taking notes in front of a laboratory's microscope. Shi anticipates a substantial decrease in pulmonary vascular resistance, the main outcome of the trial, of 20%, which is regarded as a definite success. If the results are encouraging, TPIP may replace Tyvaso, the current standard treatment. On June 4, Wells Fargo reaffirmed its Buy recommendation, with a price objective of $107. Shi points out that TPIP's once-daily dosage is a significant benefit over Tyvaso's four-times-daily schedule, which could increase adherence and make it more appealing to patients as well as physicians. The efficacy potential of TPIP is supported by interim study results that show additional advantages in six-minute walk distance (6MWD). Shi expects significant market penetration in light of these considerations, which could lead to an increase in Insmed Incorporated (NASDAQ:INSM)'s valuation. Both analysts highlight that if future trial results live up to predictions, TPIP has the potential to completely change the way that PAHs are treated. Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical firm that improves the lives of individuals suffering from serious and rare diseases. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Medication
US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Medication

Yahoo

time27 minutes ago

  • Yahoo

US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Medication

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S. Court of Appeals maintained the legality of its composition of matter patent for the medication Nuplazid, which treats psychosis in Parkinson's disease. A research scientist looking through a microscope in a lab, symbolizing the biopharmaceutical company's innovative approach to medical treatments. The verdict supports ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in its legal struggle with India-based MSN Laboratories and upholds a December 2023 ruling by the U.S. District Court of Delaware. A later patent claim with the same priority date cannot be declared invalid by the court. According to CEO Catherine Owen Adams, Nuplazid's patent protection has been extended to 2030. The 34 mg capsule is also protected by a separate formulation patent that runs through 2038. The U.S. FDA authorized Nuplazid in 2016 to treat delusions and hallucinations linked to psychosis in Parkinson's disease. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)'s legal stance in a different action against Aurobindo Pharma was further strengthened by the latest decision. When taken as a whole, these results solidify the company's portfolio of intellectual property in the face of generic competition, guaranteeing prolonged market exclusivity for its flagship neurological medication. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical firm that specializes in the creation and marketing of medications that treat uncommon diseases and disorders of the central nervous system. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26

Yahoo

time27 minutes ago

  • Yahoo

TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26

Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon hGH (lonapegsomatropin) with TransCon CNP (navepegritide) raised annualized growth velocity (AGV) and height Z-scores in children with achondroplasia. A close-up view of a hand manipulating a syringe while delivering TransCon CNP into a tumor. A mean AGV of 9.14 cm/year and a +0.53 Z-score rise were attained by treatment-naïve youngsters (N=12). Children (N=9) treated with TransCon CNP in the past achieved an AGV of 8.25 cm/year with a +0.44 Z-score improvement. The majority of side effects were modest, and safety remained consistent with monotherapies. The COACH Trial is the first to assess this combination in kids between the ages of two and eleven. While TransCon CNP is undergoing FDA priority review, TransCon hGH is approved as SKYTROFA® for juvenile growth hormone insufficiency. The treatment focuses on the FGFR3-CNP signaling imbalance that is at the heart of achondroplasia, a disorder that affects more than 250,000 people worldwide. It is anticipated that the results of week 52 and a scheduled Phase 3 trial in Q4 2025 will further clarify efficacy and long-term benefits. The biopharmaceutical business Ascendis Pharma A/S (NASDAQ:ASND) uses its TransCon technology platform to significantly improve patient outcomes. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store